A Retrospective Observational Study to Evaluate the Clinical Outcomes and Routine Management of Patients With Chronic Lymphocytic Leukaemia Treated With Idelalisib and Rituximab in the United Kingdom (UK) and Ireland
Phase of Trial: Phase IV
Latest Information Update: 06 Nov 2019
Price : $35 *
At a glance
- Drugs Idelalisib (Primary) ; Rituximab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Acronyms RETRO-idel
- Sponsors Gilead Sciences
- 06 Nov 2019 Results released at the 61st Annual Meeting and Exposition of the American Society of Hematology.
- 11 Apr 2019 Status changed from recruiting to completed.
- 11 Jan 2019 Planned End Date changed from 1 Dec 2018 to 1 Mar 2019.